Download PDF
Methods Inf Med 1971; 10(01): 1-8
DOI: 10.1055/s-0038-1636028
Original Article
Schattauer GmbH

Statistical Aspects of Monitoring for Dangers in Drug Therapy[*])

STATISTISCHE ASPEKTE DER ERFASSUNG VON ARZNEIMITTEL-NEBENWIRKUNGEN
D. J. FINNEY
1   From the Department of Statistics, The University, Edinburgh, Scotland
› Author Affiliations
Further Information

Publication History

Publication Date:
08 February 2018 (online)

    Permissions and Reprints

A therapeutic drug has a complicated life history, and some of the important stages of this are described in the paper. Before it can even be referred to as a drug, it must be identified as a chemical compound worth investigation as possibly having useful pharmacological properties. From among large numbers in this category, a few must be selected by a screening process. Toxicity tests and clinical trials each bring their special problems for the statistician. When a new drug has had its usefulness established, standardization of its potency by biological assay may be necessary, and this also uses statistical techniques.

Most of the paper is concerned with adverse reactions to drugs when used in medical practice, and methods for detecting these. In response to recent recognition of dangers, systems for monitoring for adverse reactions to drugs that occur during normal therapeutic use have been developed in many countries. The paper outlines the logical basis of monitoring and discusses its practical implementation. New problems of statistical inference, as well as large data handling activities, arise in connexion with the interpretation of evidence that is very heterogeneous in origin. The basic statistical problem appears to be one of collecting and evaluating information that may constitute a degree of suspicion calling for intensive and more objectively planned research. This type of inference seems closer to the mode of thought of a criminal investigation department than to orthodox practice of statistical estimation or decision-making; I think it has new features that deserve further study.

National monitoring organizations are now cooperating, through the World Health Organization, in an international project for the combination of evidence.

Ein Arzneimittel hat eine komplizierte Entwicklungsgeschichte; einige der Stadien dieser Entwicklung werden in der vorliegenden Arbeit beschrieben. Bevor es überhaupt als Droge angesprochen werden ▪ kann, muß es als chemische Substanz identifiziert sein, deren mögliche pharmakologische Eigenschaften weitere Untersuchungen rechtfertigen. Von vielen Stoffen in dieser Kategorie werden einige durch Voruntersuchungen ausgewählt. Toxizitätstests und klinische Prüfungen stellen den Statistiker vor ganz spezielle Probleme. Wenn die Nützlichkeit einer neuen Droge erwiesen ist, kann es notwendig werden, ihre Wirksamkeit im biologischen Versuch zu standardisieren; auch hierfür werden statistische Verfahren benötigt.

Die vorliegende Arbeit befaßt sich vor allem mit den Nebenwirkungen der Arzneimittel in der ärztlichen Praxis und den Methoden, diese zu erkennen. Als Reaktion auf kürzlich erkannte Gefahren sind in vielen Ländern Systeme zur Überwachung von Arzneimittel-Nebenwirkungen entwickelt worden. Die Arbeit umreißt die logische Grundlage soldier Monitor-Systeme und erörtert ihre praktische Durchführbarkeit. In Verbindung mit dem Nachweis der sehr heterogen bedingten Evidenz treten neue Probleme der statistischen Schlußfolgerung sowie der Verarbeitung großer Datenmengen auf. Als wesentlichstes statistisches Problem wird die Sammlung und Bewertung von Information erachtet, die einen Grad von Verdacht erweckt, der intensive und objektiv geplante Untersuchungen veranlaßt. Diese Art von Folgerung ähnelt mehr der Arbeitsweise eines Detektivbüros als der herkömmlichen Praxis statistischer Schätzungen bzw. Entscheidungen.

Nationale Überwachungsorganisationen arbeiten heute im Rahmen der WHO in einem internationalen Gemeinschaftsprojekt zur Drogenüberwachung zusammen.

Key-Words

Drug Screening - Drug Monitoring - Adverse Drug Reactions

Schlüssel-Wörter

Arzneimittel-Testung - Arzneimittel-Nebenwirkungen - Drogen-Überwachungs-Systeme

*) Based on papers presented to the Seventh International Biometric Conference, Hannover, August 1970, and the Hungarian Pharmacological Society, Budapest, September 1970.


 

  • References

  • 1 Borda I. T., Slone D., Jick H.. Assessment of adverse reactions within a drug surveillance program. J. Amer. med. Ass 205: 645-647 1968;
    CrossrefPubMedGoogle Scholar
  • 2 Brock N., Schneider B.. Pharmacological screening of drugs by means of the therapeutic index. In De Jonge H.. (Edit.): Quantitative Methods in Pharmacology. 264-278 North Holland Publishing Company; Amsterdam: 1961
    Google Scholar
  • 3 Cornfield J.. A method of estimating comparative rates from clinical data. Applications to cancer of the lung, breast, and cervix. J. nat. Cancer Inst 11: 1269-1275 1951;
    PubMedGoogle Scholar
  • 4 Cornfield J., Haenszel W.. Some aspects of retrospective studies. J. chron. Dis 11: 523-534 1970;
    PubMedGoogle Scholar
  • 5 Coull D. C., Marron A. C., Crooks J., Weir R. D.. Drug monitoring services in the health services. Hlth Bull. (Edinb) 26: 38-40 1968;
    PubMedGoogle Scholar
  • 6 Crooks J., Calder G., Weir R. D.. Drugs in hospital. J. roy. Coll. Phys 01: 233-244 1968;
    PubMedGoogle Scholar
  • 7 Davies O. L.. The design of screening tests in the pharmaceutical industry. Bull. int. statist. Inst 36: 226-241 1958;
    PubMedGoogle Scholar
  • 8 Davies O. L.. Screening for improved mutants in antibiotic research. Biometrics 20: 576-591 1964;
    CrossrefPubMedGoogle Scholar
  • 9 Dunnett C. W.. On selecting the largest of k normal population means. J. roy. statist. Soc. B 22: 1-40 1960;
    PubMedGoogle Scholar
  • 10 Dunnett C. W.. Statistical theory of drug screening. In de Jonge H.. (Edit.): Quantitative Methods in Pharmacology. 212-231 North Holland Publishing Company; Amsterdam: 1961
    Google Scholar
  • 11 Finney D. J.. Placebomania and the interpretation of clinical trials. J. New Drugs 02: 333-343 1962;
    CrossrefPubMedGoogle Scholar
  • 12 Finney D. J.. An international drug safety program. J. New Drugs 03: 262-265 1963;
    CrossrefPubMedGoogle Scholar
  • 13 Finney D. J.. Screening processes: Problems and illustrations. Contribution to statistics presented to Professor P. C. Mahalanobis. Statistical Publishing Society; Calcutta: 1964
    Google Scholar
  • 14 Finney D. J.. An international drug safeguard plan. J. chron. Dis 17: 565-581 1964;
    CrossrefPubMedGoogle Scholar
  • 15 Finney D. J.. Le controle des medicaments et la securité des medicaments. Biométrie-Praximétrie 05: 3-19 1964;
    PubMedGoogle Scholar
  • 16 Finney D. J.. Statistical Methods in Biological Assay. (2nd edition).. Griffin and Co; London: 1964
    Google Scholar
  • 17 Finney D. J.. The design and logic of a monitor of drug use. J. chron. Dis 18: 77-98 1965;
    CrossrefPubMedGoogle Scholar
  • 18 Finney D. J.. The vital statistics of a drug. Biometr. Z 08: 15-31 1966;
    CrossrefPubMedGoogle Scholar
  • 19 Finney D. J.. Monitoring adverse reactions to drugs — its logic and its weaknesses. Proceed. Europ. Soc. Study Drug Toxicity 07: 198-207 1966;
    PubMedGoogle Scholar
  • 20 Hill A. B.. Medical ethics and controlled trials. Brit, med. J 1963; 01: 1043-1049.
    CrossrefPubMedGoogle Scholar
  • 21 Hurwitz N. A., Wade O. L.. Intensive hospital monitoring of adverse reactions to drugs. Brit. med. J 1969; I: 531-536.
    PubMedGoogle Scholar
  • 22 Inman W. H. W.. The reporting of adverse reactions to drugs – The British System. Proceed. Europ. Soc. Study Drug Toxicity 07: 191-197 1966;
    PubMedGoogle Scholar
  • 23 Inman W. H. W.. Role of drug-reaction monitoring in the investigation of thrombosis and the »pill«. Brit. med. Bull 26: 248-256 1970;
    CrossrefPubMedGoogle Scholar
  • 24 Inman W. H. W., Adelstein A. M.. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 02: 279-285.
    PubMedGoogle Scholar
  • 25 Inman W. H. W., Vessey M. P.. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Brit. med. J 1968; 02: 193-199.
    CrossrefPubMedGoogle Scholar
  • 26 Inman W. H. W., Vessey M. P., Westerholm B., Engelund A.. Thromboembolic disease and the steroidal content of oral contraceptives. Brit. med. J 1970; 02: 203-209.
    CrossrefPubMedGoogle Scholar
  • 27 King E. P.. A statistical design for drug screening. Biometrics 19: 429-440 1963;
    CrossrefPubMedGoogle Scholar
  • 28 Koch-Weser J., Sidel V. W., Sweet R. H., Kanarek P., Eaton A. E.. Factors determining physician reporting of adverse drug reactions. New Engl. J. Med 280: 20-26 1969;
    CrossrefPubMedGoogle Scholar
  • 29 Lenz W.. Kindliche Mißbildungen nach Medikament-Einnahme während der Gravidität. Dtsch. med. Wschr 86: 2555-2556 1961;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Lenz W.. Thalidomide and congenital abnormalities. Lancet 1962; I: 45.
    PubMedGoogle Scholar
  • 31 Litchfield J. T.. Forecasting drug effects in man from studies in laboratory animals. J. Amer. med. Ass 177: 34-38 1961;
    CrossrefPubMedGoogle Scholar
  • 32 Marks J.. Placebomania. J. New Drugs 02: 71-77 1962;
    CrossrefPubMedGoogle Scholar
  • 33 Paget G. P.. Toxicity tests: A guide for clinicians. J. New Drugs 02: 78-83 1962;
    CrossrefPubMedGoogle Scholar
  • 34 Pike M. C., Morrow R. H.. Statistical analysis of patient-control studies in epidemiology. Brit. J. prev. soc. Med 24: 42-44 1970;
    PubMedGoogle Scholar
  • 35 Seidl L. G., Thornton G. F., Smith J. W., Cluff L. E.. Studies on the epidemiology of adverse drug reactions. 3. Reactions in patients on a general medical service. Bull. Johns Hopkins Hosp 119: 299-315 1966;
    PubMedGoogle Scholar
  • 36 Sidel V. W., Koch-Weser J., Barnett G. O., Eaton A.. Drug utilisation and adverse reactions in a general hospital. Hospitals 41: 80-88 1967;
    PubMedGoogle Scholar
  • 37 Slone D., Jick H., Borda I. T., Chalman T. C., Feinleib M., Muench H., Lepworth L., Bellotti C., Gilman B.. Drug surveillance utilising nurse monitors. Lancet 1966; 02: 901-903.
    PubMedGoogle Scholar
  • 38 Vessey M. P., Doll R., Fairbairn A. S., Glober G.. Postoperative thromboembolism and the use of oral contraceptives. Brit. med. J 1970; 03: 123-126.
    CrossrefPubMedGoogle Scholar
  • 39 Zbinden G.. Experimental and clinical aspects of drug toxicity. Advanc. Pharmacol 02: 1-112 1963;
    PubMedGoogle Scholar
  • 40 Zbinden G.. The significance of pharmacologic screening tests in the preclinical safety evaluation of new drugs. J. New Drugs 06: 1-7 1966;
    CrossrefPubMedGoogle Scholar
  • 41 Zbinden G.. Drug safety: Experimental programs. Science 164: 643-647 1969;
    CrossrefPubMedGoogle Scholar
  • 42 Zbinden G.. Usefulness of animal models in drug toxicology. Paper read to Seventh International Biometric Conference, Hannover, August. 1970
    PubMedGoogle Scholar
  • 43 Anonymous: Risk of thromboembolic disease in women taking oral contraceptives. (A preliminary communication to the Medical Research Council by a Subcommittee). Brit, med. J 1967; 02: 355-369.
    CrossrefPubMedGoogle Scholar
  • 44 Anonymous: International drug monitoring –The role of the hospital. (Report of a WHO meeting). WHO Technical Report Series no. 425; Geneva: 1969
    Google Scholar
  • 45 Anonymous: Combined oral contraceptives. (A statement by the Committee on Safety of Drugs). Brit. med. J 1970; 02: 231-232.
    CrossrefPubMedGoogle Scholar